Tremor, Limb
Conditions
Keywords
Upper Limb, Tremor, task-dependent
Brief summary
Task-dependent upper limb tremor is a disorder that frequently impairs patients' function and quality of life. Few studies exist that quantify the improvements in motor performance and disability with botulinum toxin (injections). The study team aims to perform an exploratory pilot trial using toxin Type A (Dysport) in 25 patients with task-dependent upper limb tremor, to refine quantitative measures of performance using blinded video analysis, demonstrate efficacy and tolerability of injections, and provide power calculations for a potential future multi-centered double blinded clinical trial.
Interventions
Dosing will be determined at each study visit based upon muscles involved
OTHERPlacebo
Dosing will be determined at each study visit based upon muscles involved
Sponsors
Ipsen
David M. Simpson
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Videos will be randomly provided to an outside assessor to determine benefit as a secondary outcome measure
Intervention model description
Participants are randomized to receive either study drug or placebo at the initial phase and cross over 12 weeks later and receive the alternative treatment
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with task-dependent essential tremor in upper limb. Tremor is present during at least one of the study functional tasks i. pointing task (touch between nose and a pen held 2 ft. in front. ii. pouring task (cup: pouring water out/in). iii. feeding task (weighted fork from plate on table to mouth). iv. string instrument bowing or holding instrument in static position. v. computer mouse (simple vertical or horizontal movements). * Patients must be capable of performing informed consent. * Patients on stable medications for treatment of task-dependent essential tremor for 1 month prior to study entry and maintain them throughout the study. * Patients previously treated with BoNT of any type must have occurred no sooner than 12 weeks prior to study entry.
Exclusion criteria
* Patients with no presence of tremor during study functional tasks. * Presence of tremor during the functional task is below minimum amplitude required to be considered for injection based upon investigator's clinical judgment. * Patients with unstable medical conditions or psychiatric conditions. * Patients with a medical condition that precludes them from receiving BoNT injections. * Pregnant women, or premenopausal women not willing to use contraceptive measures throughout the duration of the study. * Lithium, Valproic acid, Amiodarone, typical and atypical neuroleptics. Exposure to other than the listed tremorogenic or potentially tremorogenic drugs is allowed only if, in the opinion of the investigator, this will not interfere with the study drug evaluations.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient's Impression of Change | Week 6 | The principal outcome measure will be patient's impression of change using visual analog scale. Visual Analog Scale (VAS) 100 point scale from 0 (no improvement) to 100 (normal use). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Physician Global Impression of Change | Week 6 | Physician global impression of change is measured by using a visual analog scale. The CGI using a VAS is rated on a 100-point scale, with the severity of illness scale using a range of responses from 0 (no improvement) through to 100 (normal use).illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). |
Countries
United States
Contacts
Primary ContactMary-Catherine George
Outcome results
None listed